Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11694449 | 0.94 | ALDH1A1 (0.48) | ALDH1A1FFAR4FFAR1TSHRLMNA | |
| SCHEMBL11693825 | 0.94 | ALDH1A1 (0.48) | ALDH1A1FFAR4FFAR1TSHRLMNA | |
| SCHEMBL28453481 | 0.88 | ALDH1A1 (0.45) | ALDH1A1FFAR4FFAR1TSHRLMNA | |
| SCHEMBL5694365 | 0.87 | ZDHHC7 (0.52) | ALDH1A1TSHRLMNATDP1MEN1 | |
| SCHEMBL9794608 | 0.86 | TSHR (0.48) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL11648130 | 0.85 | ZDHHC7 (0.48) | ALDH1A1TSHRLMNATDP1MEN1 | |
| SCHEMBL11526413 | 0.84 | TSHR (0.54) | ALDH1A1TSHRLMNAPPARGPPARA | |
| SCHEMBL11524968 | 0.84 | TSHR (0.54) | ALDH1A1TSHRLMNAPPARGPPARA | |
| SCHEMBL11526472 | 0.84 | TSHR (0.54) | ALDH1A1TSHRLMNAPPARGPPARA | |
| SCHEMBL11402214 | 0.84 | ALDH1A1 (0.50) | ALDH1A1FFAR4FFAR1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| EP-2539364-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2013-01-02 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | ALDH1A1 4358/4885FFAR4 30/4885FFAR1 32/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | ALDH1A1 4511/4885FFAR4 34/4885FFAR1 37/4885 |
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | ALDH1A1 4086/4885FFAR4 151/4885FFAR1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.